{"id":5287,"date":"2012-06-29T00:00:00","date_gmt":"2012-06-29T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/index.php\/2012\/06\/29\/pmn116-article04short\/"},"modified":"2019-02-18T20:15:03","modified_gmt":"2019-02-18T20:15:03","slug":"pmn116-article04short","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmn116-article04short\/","title":{"rendered":"Are Some DTC Print Ads Too Educational and\/or Persuasive?"},"content":{"rendered":"

Are Some DTC Print Ads Too Educational and\/or Persuasive? \"FDAThe FDA often describes itself as a “data-driven” agency. That’s an understatement as far as approving drugs for marketing is concerned. FDA’s Office of Prescription Drug Promotion (OPDP) also wants to rely on robust data before it issues guidelines for advertising. Consequently, it often holds public hearings to learn from experts what research may be necessary to answer its questions about the impact of direct-to-consumer (DTC) or health professional advertising.<\/p>\n

Sometimes, however, it seems that the FDA uses studies to “table” or delay issuing guidelines. See, for example, “FDA’s Proposed Web Study Will Further Delay Social Media Guidelines<\/a>” and “A Cautionary Tale for Anyone Expecting FDA Social Media Guidelines Any Time Soon<\/a>.”<\/p>\n

Recently, two FDA studies were in the news: “Disease Information in Branded Promotional Material” and “Effect of Promotional Offers in Direct-to-Consumer Prescription Drug Print Advertisements on Consumer Product Perceptions.” The focus of both these studies will be on print ads.<\/p>\n

Key takeaways and topics covered: <\/p>\n